A highly impactful medication for combating obesity and diabetes may have a manufacturing cost as low as $3 per month once its patent expires later in the current month, according to recent findings by researchers, presenting a significant avenue for improving global health outcomes, particularly in developing economies.
Semaglutide, the core active compound in Novo Nordisk’s widely recognized Ozempic and Wegovy therapeutic agents, demonstrably facilitates substantial weight reduction in individuals, thereby offering considerable assistance in the management of diabetes and other health complications linked to excess body weight.
The patent protection for semaglutide is slated to expire in key markets such as Brazil, China, and India within the month, and an analysis by researchers has identified 150 nations where the compound has never been subject to patent restrictions.
Leveraging pricing data from analogous pharmaceuticals that recently transitioned to generic availability, a collaborative team of researchers from the United Kingdom, South Africa, and New Zealand undertook an estimation of the projected generic production cost for semaglutide.
Their projections suggest that the expenditure for producing a one-month supply of semaglutide could be as modest as $3, a stark contrast to its current retail price of approximately $200 per month in the United States when sold under its brand name.
Dr Samuel Cross, affiliated with Imperial College London and a contributor to the study, emphasized that obesity and diabetes are chronic conditions that significantly elevate the susceptibility to a range of serious ailments, including stroke, cardiovascular disease, renal insufficiency, and various forms of cancer.
“Should the production of generic versions lead to the establishment of economically viable pricing, access to treatment could be extended to millions more individuals,” he commented.
Worldwide, a vast number of individuals are affected by Type 2 diabetes, a condition that carries the severe potential for leading to kidney failure, vision impairment, and limb amputation.
On a global scale, clinically defined obesity is a contributing factor to an estimated 3.7 million fatalities annually.
The research indicates that the 160 countries where semaglutide will not be subject to patent regulations collectively represent 69 percent of the global population diagnosed with Type 2 diabetes and 84 percent of individuals classified as clinically obese.
Professor Francois Venter, a co-author of the study from the University of the Witwatersrand in South Africa, pointed out that medications used to manage conditions such as HIV, tuberculosis, malaria, and hepatitis are now accessible at prices closely aligned with their production costs, while still ensuring profitability for generic manufacturers.
“This successful precedent in medical treatment accessibility can be replicated for semaglutide,” he stated.
The researchers have disclosed their findings directly, opting for immediate dissemination rather than publication in a traditional peer-reviewed scientific journal.
